How GLP-1 and Dual GIP/GLP-1 Drugs Work in the Body
Released · Last reviewed
Semaglutide activates the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors. Both slow gastric emptying and reduce appetite; tirzepatide's dual action may explain its larger average weight loss.
- GLP-1 and GIP are natural incretin hormones released after eating.
- Semaglutide mimics GLP-1; tirzepatide mimics both GLP-1 and GIP.
- Both slow gastric emptying, increase satiety, and improve glucose control.
- Dual agonism is the leading explanation for tirzepatide's larger average effect.
The incretin system
After you eat, your gut releases incretin hormones that signal the pancreas to release insulin and the brain to register fullness. Two of these are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 receptor agonists like semaglutide are synthetic versions that activate this system more powerfully and for longer than the natural hormone.
This is why the drug class is described as incretin-based: it amplifies a signaling system the body already uses to regulate appetite and blood sugar.
How semaglutide works
Semaglutide binds the GLP-1 receptor, producing several effects: it slows gastric emptying so food stays in the stomach longer, it acts on brain centers that regulate appetite to increase satiety and reduce hunger, and it enhances glucose-dependent insulin release. Together these reduce calorie intake and improve blood sugar.
The slowed gastric emptying is also why nausea is the most common side effect, and why the drug is titrated slowly.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP |
| Gastric emptying | Slowed | Slowed |
| Appetite | Reduced | Reduced (often more) |
| Avg weight loss | Strong | Greater |
How tirzepatide adds GIP
Tirzepatide activates the GLP-1 receptor and, additionally, the GIP receptor. GIP is another incretin hormone, and adding its activity appears to enhance the metabolic and appetite-suppressing effects for many people. This dual mechanism is the leading explanation for tirzepatide's larger average weight loss in trials like SURMOUNT-5.
The exact contribution of GIP is still an active research area, but the clinical signal — greater average weight loss with the dual agonist — is consistent across studies.
| Effect | Result |
|---|---|
| Slowed gastric emptying | Longer fullness, less intake |
| Appetite signaling | Reduced hunger |
| Insulin release | Better glucose control |
What the mechanism means for you
Understanding the mechanism clarifies a few practical points. The appetite reduction is central and physiological, not willpower; the slow titration exists because the same mechanism that suppresses appetite also causes GI effects; and the dual mechanism of tirzepatide is why it tends to produce more weight loss, not marketing.
It also explains why stopping the drug tends to bring appetite back: you are removing an amplified satiety signal, and the body returns to its prior set point. This is why these drugs are framed as long-term therapies.
Frequently asked questions
What is the difference between semaglutide and tirzepatide mechanism?
Semaglutide activates one incretin receptor (GLP-1); tirzepatide activates two (GLP-1 and GIP). The dual action may explain tirzepatide's larger average weight loss.
Why do these drugs reduce appetite?
They activate GLP-1 (and for tirzepatide, GIP) receptors, slowing gastric emptying and acting on brain appetite centers to increase fullness and reduce hunger.
Why does appetite return after stopping?
The drugs amplify a natural satiety signal. Removing them lets appetite return toward its prior level, which is why they are used long-term.
Sources
- Clinical trials via NEJM.
- Incretin physiology and GLP-1/GIP pharmacology literature.
- FDA — human drug compounding and GLP-1 status.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
What we do not claim in tirzepatide
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We show month-to-month and prepaid figures side by side for that reason. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.